Melatonin prevents experimental preterm labor and increases offspring survival

Area of Science:

• Reproductive biology
• Pharmacology
• Neonatal health

Background:

• Preterm delivery is a major cause of neonatal mortality and developmental issues.
• Intra-amniotic infections are a significant, potentially preventable cause of preterm birth.
• Current therapies for preventing preterm labor are limited.

Purpose of the Study:

• To investigate the efficacy of melatonin in preventing inflammation-associated preterm delivery.
• To assess melatonin's impact on fetal outcomes and inflammatory markers in a murine model.
• To explore melatonin as a potential therapeutic agent for preterm birth.

Main Methods:

• Preterm labor was induced in BALB/c mice using bacterial lipopolysaccharide (LPS).
• Melatonin was administered via subcutaneous implantation on day 14 of pregnancy.
• Uterine prostaglandin (PG) levels, nitric oxide (NO) production, and inflammatory markers (cyclooxygenase-2, inducible NO synthase, tumor necrosis factor-alpha) were measured.

Main Results:

• Melatonin treatment prevented preterm birth in 50% of LPS-exposed mice, with all surviving pups born healthy.
• Melatonin significantly inhibited LPS-induced increases in uterine PGE2, PGF2α, cyclooxygenase-2, NO production, inducible NO synthase, and TNFα.
• Control LPS-treated animals exhibited 100% preterm birth incidence and fetal damage.

Conclusions:

• Melatonin demonstrates a protective effect against inflammation-induced preterm labor in a murine model.
• Melatonin normalizes key inflammatory pathways involved in preterm birth, including prostaglandins and nitric oxide.
• Melatonin represents a promising therapeutic candidate for preventing preterm labor and enhancing neonatal survival.